A study published in The Lancet showed 48% of type 2 diabetes patients who took Takeda Pharmaceuticals' TAK-875 for 12 weeks achieved blood glucose levels below a predetermined level, compared with 40% of those who received glimepiride. Researchers also found that 2% of patients who took TAK-875 developed hypoglycemia, compared with 19% in the glimepiride group.

Full Story:

Related Summaries